
Ceribell Inc (CBLL) Stock Forecast & Price Target
Ceribell Inc (CBLL) Analyst Ratings
Bulls say
CeriBell is attractive fundamentally because it combines a first-mover position in point-of-care rapid EEG with a differentiated AI-enabled platform that addresses an underserved ICU and ED workflow, allowing bedside deployment in minutes and supporting faster, more data-driven treatment decisions. Its outlook is reinforced by sustained near-30% sales growth, a raised FY26 revenue guide of $114M-$117M, 92.3% gross margin, 712 active hospitals, and a still-low sub-4% penetration in the core seizure market, which leaves substantial room for expansion. Additional upside comes from FDA-cleared pediatric/neonate and delirium indications, a late-stage stroke program, and a product pipeline that should deepen utilization, widen its $3.5B+ TAM, and support eventual profitability with cash on hand.
Bears say
CeriBell is facing a weak fundamental setup driven by subpar financial results, slower-than-expected adoption, and the risk that expanded indications such as delirium and stroke fail to deliver meaningful clinical or commercial upside. Heightened competition from conventional EEG systems and new point-of-care offerings, along with unfavorable insurance coverage and reimbursement dynamics, could further pressure utilization and limit pricing power, while delays in new product launches would postpone revenue contribution. Additional downside comes from potential tariff increases on imports from China or a ban on Chinese imports, which could compress gross margins and force more sourcing from Vietnam.
This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Ceribell Inc (CBLL) Forecast
Ceribell Inc (CBLL) Analyst Forecast & Price Prediction
Start investing in Ceribell Inc (CBLL)
Order type
Buy in
Order amount
Est. shares
0 shares